MX2009007089A - Preparacion farmaceutica liposomal y metodo para su elaboracion. - Google Patents
Preparacion farmaceutica liposomal y metodo para su elaboracion.Info
- Publication number
- MX2009007089A MX2009007089A MX2009007089A MX2009007089A MX2009007089A MX 2009007089 A MX2009007089 A MX 2009007089A MX 2009007089 A MX2009007089 A MX 2009007089A MX 2009007089 A MX2009007089 A MX 2009007089A MX 2009007089 A MX2009007089 A MX 2009007089A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- liposome formulation
- liposome
- body temperature
- phospholipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una preparación farmacéutica liposomal que contiene un fármaco iónico multivalente, un procedimiento para la preparación de la preparación farmacéutica liposomal, y su uso en el tratamiento de enfermedades, en donde el liposoma tiene un tamaño de aproximadamente 30-80 nm, y la bicapa de fosfolípido tiene un fosfolípido con una Tm más alta que la temperatura corporal, de modo que la temperatura de transición de fase del liposoma es más alta que la temperatura corporal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101023398A CN101209243B (zh) | 2006-12-29 | 2006-12-29 | 一种脂质体药物及其制备方法 |
PCT/CN2007/071403 WO2008080367A1 (fr) | 2006-12-29 | 2007-12-29 | Composition de liposome et son procédé de préparation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009007089A true MX2009007089A (es) | 2009-10-08 |
Family
ID=39588170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009007089A MX2009007089A (es) | 2006-12-29 | 2007-12-29 | Preparacion farmaceutica liposomal y metodo para su elaboracion. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20110002977A1 (es) |
EP (1) | EP2123260B1 (es) |
JP (3) | JP2010514708A (es) |
KR (1) | KR101126629B1 (es) |
CN (1) | CN101209243B (es) |
AU (1) | AU2007341803B2 (es) |
BR (1) | BRPI0720733A2 (es) |
CA (1) | CA2673924C (es) |
CO (1) | CO6190601A2 (es) |
CU (1) | CU23980B1 (es) |
ES (1) | ES2401526T3 (es) |
HK (1) | HK1133398A1 (es) |
MX (1) | MX2009007089A (es) |
MY (1) | MY150670A (es) |
RU (1) | RU2494729C2 (es) |
WO (1) | WO2008080367A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101209243B (zh) | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种脂质体药物及其制备方法 |
US20090136937A1 (en) | 2007-05-09 | 2009-05-28 | Coleman Matthew A | Methods and systems for monitoring production of a target protein in a nanolipoprotein particle |
US20110223675A1 (en) * | 2008-11-20 | 2011-09-15 | Terumo Kabushiki Kaisha | Drug release means from liposomes and method for evaluating releasability |
JP5622719B2 (ja) | 2009-03-30 | 2014-11-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
DK2415470T3 (en) * | 2009-03-30 | 2016-09-19 | Eisai R&D Man Co Ltd | liposome |
AU2014200717B2 (en) * | 2009-03-30 | 2016-02-25 | Eisai R&D Management Co., Ltd. | Liposome composition |
CN101897667B (zh) * | 2009-05-26 | 2012-01-25 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸多柔比星脂质体注射剂及其制备工艺 |
IN2012DN00570A (es) * | 2009-07-14 | 2015-06-12 | Polypid Ltd | |
CN102038640B (zh) * | 2009-10-26 | 2013-11-13 | 石药集团中奇制药技术(石家庄)有限公司 | 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法 |
WO2011143271A2 (en) * | 2010-05-10 | 2011-11-17 | Schmidt Michael A | Therapeutic liposomes and methods for producing and using the same |
CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
US20150283272A1 (en) * | 2010-10-27 | 2015-10-08 | Vikas Kundra | Dual mode gadolinium nanoparticle contrast agents |
US20140328759A1 (en) * | 2011-10-25 | 2014-11-06 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
US9644038B2 (en) | 2011-12-21 | 2017-05-09 | The Regents Of The University Of California | Apolipoprotein nanodiscs with telodendrimer |
TR201908531T4 (tr) * | 2012-11-20 | 2019-08-21 | Arbutus Biopharma Corp | Terapöti̇k kullanim i̇çi̇n li̇pozom kapsüllü vi̇nkri̇sti̇ni̇n preparasyonuna yöneli̇k geli̇şti̇ri̇lmi̇ş yöntem |
US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
CA2906732C (en) | 2013-03-15 | 2023-08-08 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
US10220095B2 (en) | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
KR101503492B1 (ko) * | 2013-07-03 | 2015-03-19 | 전북대학교산학협력단 | 지질 및 리소좀 효소를 포함하는 리포좀 캡슐 및 그 제조방법 |
WO2015166985A1 (ja) * | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
WO2015166986A1 (ja) * | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
WO2017044899A1 (en) | 2015-09-11 | 2017-03-16 | Lawrence Livermore National Security, Llc | Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation |
CN111632030B (zh) | 2015-11-02 | 2023-01-17 | 富士胶片株式会社 | 包含吉西他滨或其盐的脂质体组合物的制造方法 |
IL268099B1 (en) * | 2017-01-18 | 2024-01-01 | Temasek Life Sciences Laboratory Ltd | Hyperstabilized liposomes that increase targeting of mitotic cells |
WO2018204421A2 (en) | 2017-05-02 | 2018-11-08 | Lawrence Livermore National Security, Llc | Momp telonanoparticles, and related compositions, methods and systems |
WO2018204495A1 (en) * | 2017-05-02 | 2018-11-08 | Synthetic Genomics, Inc. | Nanolipoprotein particles and related compositions methods and systems for loading rna |
US11433143B2 (en) * | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
RU2728976C2 (ru) * | 2018-03-22 | 2020-08-03 | Зули Холдингз, Лтд. | Липосомный состав и его получение |
CN108721644B (zh) * | 2018-06-05 | 2021-06-08 | 常州金远药业制造有限公司 | 一种紫杉烷类药物脂质体制备方法 |
CN110711178A (zh) | 2018-07-11 | 2020-01-21 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
CA3167470A1 (en) * | 2020-02-10 | 2021-08-19 | Chunlei Li | Use of mitoxantrone hydrochloride liposome for treating breast cancer |
WO2021180184A1 (zh) * | 2020-03-12 | 2021-09-16 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体的用途 |
WO2021208842A1 (zh) * | 2020-04-13 | 2021-10-21 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体的用途 |
CN113876711A (zh) * | 2020-07-01 | 2022-01-04 | 江苏长泰药业有限公司 | 一种盐酸阿霉素脂质体的制备工艺 |
JP2023537049A (ja) | 2020-08-07 | 2023-08-30 | 石薬集団中奇制薬技術(石家庄)有限公司 | ミトキサントロン塩酸塩リポソームとペグアスパラガーゼの使用 |
US20240024257A1 (en) * | 2020-08-27 | 2024-01-25 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone |
AU2021399438A1 (en) * | 2020-12-15 | 2023-07-06 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Use of mitoxantrone hydrochloride liposome |
US20240122875A1 (en) | 2021-04-16 | 2024-04-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Use of mitoxantrone hydrochloride liposome |
CN115400083A (zh) | 2021-05-28 | 2022-11-29 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体用于制备治疗晚期实体瘤的药物的用途 |
CN115770288A (zh) * | 2021-09-07 | 2023-03-10 | 石药集团中奇制药技术(石家庄)有限公司 | 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途 |
CN117940164A (zh) * | 2022-04-26 | 2024-04-26 | 石药集团中奇制药技术(石家庄)有限公司 | 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5169635A (en) * | 1989-11-17 | 1992-12-08 | Fuji Photo Film Co., Ltd. | Photoresponsive liposome |
ZA952481B (en) * | 1994-03-28 | 1995-12-15 | Daiichi Seiyaku Co | Liposomes with enhanced encapsulation capacity |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
EP0825852B1 (en) * | 1995-04-18 | 2004-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
US5858397A (en) * | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
EP1037610A4 (en) * | 1997-09-16 | 2004-07-07 | Osi Pharm Inc | COMPOSITIONS BASED ON LIPOSOMES COMPRISING CAMPTOTHECIN |
US6740335B1 (en) * | 1997-09-16 | 2004-05-25 | Osi Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
BR9914601A (pt) * | 1998-09-16 | 2001-10-23 | Alza Corp | Inibidor de topoisomerase capturado por lipossoma |
DE60014093T2 (de) * | 1999-07-16 | 2005-02-03 | Alza Corp., Mountain View | Liposomzusammensetzung mit Schutz vor Gefrier-/Aufbau-Schaden |
ES2186484B1 (es) | 2000-10-10 | 2004-07-01 | Lipotec, S.A. | Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. |
MXPA03003401A (es) | 2000-10-16 | 2004-06-30 | Neopharm Inc | Formulacion liposomica de mitoxantrona. |
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
AU2003287526A1 (en) * | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
AU2003298738A1 (en) * | 2002-11-26 | 2004-06-18 | Su-Ming Chiang | Liposomal formulations |
US7205299B2 (en) * | 2003-06-05 | 2007-04-17 | Zentaris Gmbh | Indole derivatives having an apoptosis-inducing effect |
US7288396B2 (en) * | 2003-09-11 | 2007-10-30 | Kosan Biosciences Incorporated | Biosynthetic gene cluster for leptomycins |
RU2258530C1 (ru) * | 2004-04-27 | 2005-08-20 | Генкин Дмитрий Дмитриевич | Способ профилактики и коррекции изменений кожи |
KR101223366B1 (ko) * | 2004-05-03 | 2013-01-16 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
US20060034906A1 (en) * | 2004-05-21 | 2006-02-16 | Transave, Inc. | Treatment of lung diseases and pre-lung disease conditions |
CN1242740C (zh) * | 2004-08-05 | 2006-02-22 | 常州太平洋药物研究所有限公司 | 米托蒽醌或盐酸米托蒽醌脂质体注射剂及其制备工艺 |
JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
JP2006298844A (ja) * | 2005-04-21 | 2006-11-02 | Konica Minolta Medical & Graphic Inc | リポソーム内に医薬化合物を内包するリポソーム含有製剤 |
AU2006241149A1 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
WO2007028154A2 (en) * | 2005-09-02 | 2007-03-08 | Northwestern University | Encapsulated arsenic drugs |
EP3067046B1 (en) * | 2005-12-08 | 2020-03-25 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
US7703945B2 (en) | 2006-06-27 | 2010-04-27 | Cree, Inc. | Efficient emitting LED package and method for efficiently emitting light |
CN101209243B (zh) | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种脂质体药物及其制备方法 |
DK2415470T3 (en) * | 2009-03-30 | 2016-09-19 | Eisai R&D Man Co Ltd | liposome |
JP5480867B2 (ja) * | 2011-10-07 | 2014-04-23 | 住友ゴム工業株式会社 | 空気入りタイヤ |
-
2006
- 2006-12-29 CN CN2006101023398A patent/CN101209243B/zh active Active
-
2007
- 2007-12-29 KR KR1020097015712A patent/KR101126629B1/ko active IP Right Grant
- 2007-12-29 US US12/521,357 patent/US20110002977A1/en not_active Abandoned
- 2007-12-29 MY MYPI20092715 patent/MY150670A/en unknown
- 2007-12-29 CA CA2673924A patent/CA2673924C/en active Active
- 2007-12-29 RU RU2009126983/15A patent/RU2494729C2/ru active
- 2007-12-29 WO PCT/CN2007/071403 patent/WO2008080367A1/zh active Application Filing
- 2007-12-29 EP EP07846229A patent/EP2123260B1/en active Active
- 2007-12-29 ES ES07846229T patent/ES2401526T3/es active Active
- 2007-12-29 AU AU2007341803A patent/AU2007341803B2/en active Active
- 2007-12-29 JP JP2009543335A patent/JP2010514708A/ja active Pending
- 2007-12-29 BR BRPI0720733-6A patent/BRPI0720733A2/pt not_active Application Discontinuation
- 2007-12-29 MX MX2009007089A patent/MX2009007089A/es active IP Right Grant
-
2009
- 2009-06-26 CO CO09066822A patent/CO6190601A2/es not_active Application Discontinuation
- 2009-06-29 CU CU2009000114A patent/CU23980B1/es active IP Right Grant
-
2010
- 2010-01-20 HK HK10100560.8A patent/HK1133398A1/en unknown
-
2013
- 2013-04-10 JP JP2013082307A patent/JP6187961B2/ja active Active
-
2015
- 2015-05-11 JP JP2015096518A patent/JP2015180652A/ja active Pending
-
2016
- 2016-04-26 US US15/138,527 patent/US10028913B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2007341803A2 (en) | 2009-09-03 |
AU2007341803B2 (en) | 2011-08-11 |
JP6187961B2 (ja) | 2017-08-30 |
WO2008080367A1 (fr) | 2008-07-10 |
MY150670A (en) | 2014-02-28 |
CA2673924C (en) | 2013-10-01 |
US20160235671A1 (en) | 2016-08-18 |
KR20090094043A (ko) | 2009-09-02 |
EP2123260A4 (en) | 2010-03-17 |
EP2123260B1 (en) | 2013-02-20 |
CU23980B1 (es) | 2014-01-29 |
ES2401526T3 (es) | 2013-04-22 |
RU2494729C2 (ru) | 2013-10-10 |
AU2007341803A1 (en) | 2008-07-10 |
JP2015180652A (ja) | 2015-10-15 |
CU20090114A7 (es) | 2011-02-24 |
JP2010514708A (ja) | 2010-05-06 |
CN101209243A (zh) | 2008-07-02 |
US20110002977A1 (en) | 2011-01-06 |
EP2123260A1 (en) | 2009-11-25 |
CA2673924A1 (en) | 2008-07-10 |
JP2013177397A (ja) | 2013-09-09 |
HK1133398A1 (en) | 2010-03-26 |
US10028913B2 (en) | 2018-07-24 |
RU2009126983A (ru) | 2011-02-10 |
CN101209243B (zh) | 2010-12-08 |
CO6190601A2 (es) | 2010-08-19 |
KR101126629B1 (ko) | 2012-03-26 |
BRPI0720733A2 (pt) | 2014-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009007089A (es) | Preparacion farmaceutica liposomal y metodo para su elaboracion. | |
EP2013016A4 (en) | NANOPARTICLES OF LIPOSOME AND OTHER FORMULATIONS OF FENRETINIDE USEFUL IN THERAPY AND FOR THE DELIVERY OF MEDICAMENT | |
IL179012A (en) | A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use | |
IL192104A (en) | Formulation suitable for subcutaneous administration containing molecules of ctla4ig, sugar and liquid liquid pharmacist acceptable and its use in drug preparation | |
UA106074C2 (uk) | ПОХІДНІ 1H-ІМІДАЗО[4,5-c]ХІНОЛІНОНУ | |
WO2012091523A8 (en) | Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof | |
EP1830820A4 (en) | COMPLEX FORMULATION WITH CONTROLLED RELEASE FOR THE ORAL ADMINISTRATION OF A MEDICAMENT AGAINST DIABETES AND METHOD FOR THE PRODUCTION THEREOF | |
MX362882B (es) | Composición de liposomas para usarse en diálisis peritoneal. | |
IL201176A (en) | 4-amino-1-h-pyrazolo [3,4- d] pyrimidine-3-ram-phenyl, a pharmaceutical containing them and their use in the preparation of a drug | |
IL164373A (en) | Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer | |
IL196243A (en) | [4,2,1] Triazole [3,4– a Pyridine Derivatives | |
EP2211913A4 (en) | SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS | |
BR112012003283A2 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
IL212586A (en) | Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative | |
WO2008064192A3 (en) | Modified release analgesic suspensions | |
IL197575A (en) | A method for removing adult stem cells from the blood, using them to prepare drugs for the treatment of lesions, and a medical preparation containing these adult GES cells | |
HK1109858A1 (en) | Pharmaceutical preparation for oral administration with controlled drug release in the small intestine colon and process of prepartion thereof | |
NO20054459L (no) | Liposompreparat for reduksjon av liposomindusert komplementaktivering | |
WO2011055980A3 (ko) | 산화아연-결합성 펩타이드를 포함하는 단백질과 산화아연 나노입자의 복합체 및 그의 용도 | |
WO2009001209A8 (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
EP1774975A4 (en) | USE OF A HUMAN LYSOZYM PREPARATION FOR THE TREATMENT OF ACNE | |
UA95271C2 (ru) | Применение солей тиотропия для лечения персистирующей астмы средней тяжести | |
TW200800977A (en) | A new salt | |
ZA201004644B (en) | "derivatives of 6-heterocyclic-imidazo[1,2-a]pyrroine-2-carboxamides,preparation thereof and therapeutic application thereof" | |
EA200970562A1 (ru) | Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |